Stock listing
NMRA Stock Price, News, Filings & Events — Neumora Therapeutics, Inc.
Selected listing: NMRA · BOATS · USD · US
This page tracks Neumora Therapeutics, Inc.'s NMRA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NMRA:BOATS. NMRA:BOATS is the stock-level entry point for investors researching Neumora Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Neumora Therapeutics, Inc. (ticker: NMRA) is a public company based in the United States, focusing on innovative therapeutic solutions. With a market capitalization of approximately $276 million, Neumora is dedicated to advancing treatments in the healthcare sector. The company aims to address significant unmet medical needs through its research and development efforts.
- Ticker
- NMRA:BOATS
- Asset type
- Stock
- Market cap
- $261.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BOATS
- Currency
- USD
Neumora Therapeutics, Inc. NMRA:BOATS stock context
This page tracks Neumora Therapeutics, Inc.'s NMRA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following NMRA:BOATS. NMRA:BOATS is the stock-level entry point for investors researching Neumora Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Neumora Therapeutics, Inc. (ticker: NMRA) is a public company based in the United States, focusing on innovative therapeutic solutions. With a market capitalization of approximately $276 million, Neumora is dedicated to advancing treatments in the healthcare sector. The company aims to address significant unmet medical needs through its research and development efforts.
Latest news from Neumora Therapeutics, Inc.
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
July 27, 2026
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
June 15, 2026
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Neumora Therapeutics, Inc. earnings calls
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call
March 30, 2026 · Replay with transcript and chapters
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call
August 6, 2025 · Replay with transcript and chapters
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call
May 12, 2025 · Replay with transcript and chapters
Neumora Therapeutics, Inc. (NMRA) Q4 2024 Earnings Call
March 3, 2025 · Replay with transcript and chapters
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call
November 12, 2024 · Replay with transcript and chapters
Research Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for NMRA:BOATS.
Neumora Therapeutics, Inc. company profile
View the public company page for Neumora Therapeutics, Inc. on 6ix.
Neumora Therapeutics, Inc. news
Read company news and market updates connected to Neumora Therapeutics, Inc..
Neumora Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Neumora Therapeutics, Inc..